AGTR1 | Angiotensin II receptor, type 1 | Disease related genes FDA approved drug targets G-protein coupled receptors Predicted membrane proteins Transporters
| | | | | Group enriched |
IGFBP1 | Insulin-like growth factor binding protein 1 | Candidate cardiovascular disease genes Plasma proteins Predicted secreted proteins
| | | | | Group enriched |
PEG10 | Paternally expressed 10 | Predicted intracellular proteins
| | | | | Group enriched |
ZFAT | Zinc finger and AT hook domain containing | Predicted intracellular proteins Transcription factors
| | | | | Group enriched |
ADRB1 | Adrenoceptor beta 1 | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
ALPPL2 | Alkaline phosphatase, placental-like 2 | Enzymes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
AMOT | Angiomotin | Predicted intracellular proteins
| | | | | Tissue enhanced |
C1QTNF6 | C1q and tumor necrosis factor related protein 6 | Predicted intracellular proteins
| | | | | Tissue enhanced |
CGB7 | Chorionic gonadotropin, beta polypeptide 7 | Cancer-related genes Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
COL15A1 | Collagen, type XV, alpha 1 | Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
COL4A2 | Collagen, type IV, alpha 2 | Cancer-related genes Disease related genes Plasma proteins Predicted intracellular proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CSF3R | Colony stimulating factor 3 receptor (granulocyte) | Cancer-related genes CD markers Disease related genes FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
CTAG2 | Cancer/testis antigen 2 | Cancer-related genes Predicted intracellular proteins
| | | | | Tissue enhanced |
EGFR | Epidermal growth factor receptor | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins RAS pathway related proteins
| | | | | Tissue enhanced |
ENPP1 | Ectonucleotide pyrophosphatase/phosphodiesterase 1 | CD markers Disease related genes Enzymes Potential drug targets Predicted membrane proteins
| | | | | Tissue enhanced |
FN1 | Fibronectin 1 | Cancer-related genes Candidate cardiovascular disease genes Disease related genes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted secreted proteins
| | | | | Tissue enhanced |
GDF15 | Growth differentiation factor 15 | Cancer-related genes Plasma proteins Predicted intracellular proteins Predicted secreted proteins
| | | | | Tissue enhanced |
GLDC | Glycine dehydrogenase (decarboxylating) | Disease related genes Enzymes Mitochondrial proteins Potential drug targets Predicted intracellular proteins
| | | | | Tissue enhanced |
HAPLN1 | Hyaluronan and proteoglycan link protein 1 | Predicted secreted proteins
| | | | | Tissue enhanced |
HLA-G | Major histocompatibility complex, class I, G | Cancer-related genes Predicted membrane proteins
| | | | | Tissue enhanced |
HPGDS | Hematopoietic prostaglandin D synthase | Enzymes Predicted intracellular proteins
| | | | | Tissue enhanced |
HSD17B2 | Hydroxysteroid (17-beta) dehydrogenase 2 | Enzymes Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
IDO1 | Indoleamine 2,3-dioxygenase 1 | Cancer-related genes Enzymes Predicted intracellular proteins
| | | | | Tissue enhanced |
ISYNA1 | Inositol-3-phosphate synthase 1 | Enzymes Predicted intracellular proteins
| | | | | Tissue enhanced |
LAMA2 | Laminin, alpha 2 | Disease related genes Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
LYVE1 | Lymphatic vessel endothelial hyaluronan receptor 1 | Plasma proteins Predicted membrane proteins
| | | | | Tissue enhanced |
MBNL3 | Muscleblind-like splicing regulator 3 | Predicted intracellular proteins
| | | | | Tissue enhanced |
MEOX2 | Mesenchyme homeobox 2 | Predicted intracellular proteins Transcription factors
| | | | | Tissue enhanced |
MORC4 | MORC family CW-type zinc finger 4 | Cancer-related genes Predicted intracellular proteins
| | | | | Tissue enhanced |
NFE2L3 | Nuclear factor, erythroid 2-like 3 | Plasma proteins Predicted intracellular proteins Predicted secreted proteins Transcription factors
| | | | | Tissue enhanced |
NID2 | Nidogen 2 (osteonidogen) | Plasma proteins Predicted intracellular proteins Predicted secreted proteins
| | | | | Tissue enhanced |
PDGFB | Platelet-derived growth factor beta polypeptide | Cancer-related genes Candidate cardiovascular disease genes Disease related genes Plasma proteins Predicted intracellular proteins Predicted secreted proteins RAS pathway related proteins
| | | | | Tissue enhanced |
PDPN | Podoplanin | Predicted membrane proteins
| | | | | Tissue enhanced |
PTGES | Prostaglandin E synthase | Enzymes Predicted membrane proteins
| | | | | Tissue enhanced |
RP11-872D17.8 | Uncharacterized protein {ECO:0000313|Ensembl:ENSP00000431536} | Predicted membrane proteins
| | | | | Tissue enhanced |
SLC2A1 | Solute carrier family 2 (facilitated glucose transporter), member 1 | Cancer-related genes Disease related genes Plasma proteins Potential drug targets Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
STATH | Statherin | Plasma proteins Predicted secreted proteins Transporters
| | | | | Tissue enhanced |
TFAP2A | Transcription factor AP-2 alpha (activating enhancer binding protein 2 alpha) | Disease related genes Predicted intracellular proteins Transcription factors
| | | | | Tissue enhanced |